tbuckley/cabot-search huggingface dataset:
Improved Clinical Outcome of Patients with Myelodysplastic Syndrome (MDS) Progressing after Hypomethylating Agent: In the Era of Novel Therapies
Authors: Ahmad Ghorab, Aref Al-Kali, Michelle A. Elliot, Mithun V. Shah, Jeanne M. Palmer, Hemant S. Murthy, Mohamed A. Kharfan-Dabaja, Mark R. Litzow, James M. Foran, Talha Badar
Journal: Blood (2021)
Comparison of Dimethyl Fumarate vs Fingolimod and Rituximab vs Natalizumab for Treatment of Multiple Sclerosis
Authors: Jue Hou, Nicole Kim, Tianrun Cai, Kumar Dahal, Howard Weiner, Tanuja Chitnis, Tianxi Cai, Zongqi Xia
Journal: JAMA Network Open (2021)

<h3>Importance</h3> As disease-modifying treatment options for multiple sclerosis increase, comparisons of the options based on real-world evidence may guide clinical decision-making. <h3>Objective</h3> To compare the relapse outcomes between 2 pairs of disease-modifying treatments: dimethyl fumarate vs fingolimod and natalizumab vs rituximab. <h3>Design, Setting, and Participants</h3> This comparative effectiveness study integrated data from a clinic-based multiple sclerosis research registry and its linked electronic health records (EHR) system between January 1, 2006, and December 31, 2016, and built treatment groups for each pairwise disease-modifying treatment comparison according to both registry records and electronic prescriptions. Parallel analyses were conducted from October 11, 2019, to July 7, 2021. <h3>Main Outcomes and Measures</h3> The main outcomes were the 1-year and 2-year relapse rates as well as the time to relapse. To compare relapse outcomes, the study adjusted for covariates from 2 sources (registry and EHR) and corrected for confounding biases among the covariates by the doubly robust estimation. <h3>Results</h3> The study included 4 treatment groups: dimethyl fumarate (n = 260; 198 women [76.2%]; 227 non-Hispanic White individuals [87.3%]; mean [SD] age at diagnosis, 41.7 [10.4] years), fingolimod (n = 267; 190 women [71.2%]; 222 non-Hispanic White individuals [83.1%]; mean [SD] age at diagnosis, 37.9 [9.9] years), natalizumab (n = 204; 160 women [78.4%]; 172 non-Hispanic White individuals [84.3%]; mean [SD] age at diagnosis, 37.2 [10.6] years), and rituximab (n = 115; 83 women [72.2%]; 99 non-Hispanic White individuals [86.1%]; mean [SD] age at diagnosis, 44.1 [11.1] years). No significant differences were found in the relapse outcomes between dimethyl fumarate and fingolimod after correcting for confounding biases and multiple testing (difference in 1-year relapse rate, 0.028 [95% CI, –0.031 to 0.084]; difference in 2-year relapse rate, 0.071 [95% CI, 0.008-0.128]; relative risk of 2-year non-relapse, 0.957 [95% CI, 0.884-1.035] with dimethyl fumarate as reference). When compared with rituximab, natalizumab was associated with a higher relapse rate for all 3 outcomes after bias correction and multiple testing (difference in 1-year relapse rate, 0.080 [95% CI, 0.013-0.137]; difference in 2-year relapse rate, 0.132 [95% CI, 0.043-0.189]; relative risk of 2-year non-relapse, 0.903 [95% CI, 0.822-0.944]). Confounders were identified from EHR data not recorded in the registry data through data-driven feature selection. <h3>Conclusions and Relevance</h3> This study reports real-world evidence of equivalent relapse outcomes between dimethyl fumarate and fingolimod and relapse reduction in favor of rituximab relative to natalizumab. This approach illustrates the value of incorporating EHR data as high-dimensional covariates in real-world treatment comparison.
Outcomes of Patients Treated with CPX-351 As First Line Therapy for AML Based on Their Antecedent History of Myeloid Malignancy
Authors: Akriti G Jain, Somedeb Ball, David A. Sallman, Rami S. Komrokji, Eric Padron, Andrew T. Kuykendall, Onyee Chan, Jeffrey E. Lancet, Kendra Sweet
Journal: Blood (2021)
Application Research on Optimization Algorithm of sEMG Gesture Recognition Based on Light CNN+LSTM Model
Authors: Dianchun Bai, Tie Liu, Xinghua Han, Hongyu Yi
Journal: Cyborg and Bionic Systems (2021)

The deep learning gesture recognition based on surface electromyography plays an increasingly important role in human-computer interaction. In order to ensure the high accuracy of deep learning in multistate muscle action recognition and ensure that the training model can be applied in the embedded chip with small storage space, this paper presents a feature model construction and optimization method based on multichannel sEMG amplification unit. The feature model is established by using multidimensional sequential sEMG images by combining convolutional neural network and long-term memory network to solve the problem of multistate sEMG signal recognition. The experimental results show that under the same network structure, the sEMG signal with fast Fourier transform and root mean square as feature data processing has a good recognition rate, and the recognition accuracy of complex gestures is 91.40%, with the size of 1 MB. The model can still control the artificial hand accurately when the model is small and the precision is high.
Ventral striatal islands of Calleja neurons control grooming in mice
Authors: Yun-Feng Zhang, Luigim Vargas Cifuentes, Katherine N. Wright, Janardhan P. Bhattarai, Julia Mohrhardt, David Fleck, Emma Janke, Chunjie Jiang, Suna L. Cranfill, Nitsan Goldstein, Mary Schreck, Andrew H. Moberly, Yiqun Yu, Benjamin R. Arenkiel, J. Nicholas Betley, Wenqin Luo, Johannes Stegmaier, Daniel W. Wesson, Marc Spehr, Marc V. Fuccillo, Minghong Ma
Journal: Nature Neuroscience (2021)
Abstract 9547: Prevalence and Characteristics of Registered Diabetes Clinical Trials With Cardiovascular Outcomes: An Analysis of Clinicaltrials.gov
Authors: Alexander R Zheutlin, David Caldwell, Alexander Chaitoff, Joshua Niforatos
Journal: Circulation (2021)

Introduction: Cardiovascular disease (CVD) is a well-known sequela of diabetes. Interventions to address diabetes often fail to assess clinically-relevant cardiovascular event reduction. Recently, emphasis has shifted to include CVD events in diabetes trials. We characterized diabetes trials that include CVD events as a primary or secondary outcome. Methods: Interventional (non-observational) clinical trials registered to ClinicalTrials.gov from 1/1/2009 through 12/31/2019 were abstracted. Diabetes trials and characteristics were selected from the “Clinical Trials Transformation Initiative” SQL database, using the United States National Library of Medicine medical subject heading terms (MeSH). Trials were restricted based upon inclusion of CVD (Major Adverse Cardiac Events [MACE], cardiovascular death, fatal stroke, fatal myocardial infarction [MI], non-fatal MI, non-fatal stroke) outcomes as identified in primary or secondary outcome fields. Results: Among 2470 diabetes trial, only 49 (1.9%) included CVD events as a primary or secondary outcome. Median trial size was 571 (range 12, 934000), with 40.8% including multiple sites and 42.9% including a site in the US and another country. Most trials had been completed (53.1%) and were Phase 3 or 4 (36.7% and 20.4%, respectively). Trials were predominantly randomized (91.8%), parallel assignment (89.8%), masked (75.5%), included a control arm (87.8%), and industry-funded (59.2%). Over half did not report results on ClinicalTrials.gov (55.1%). Only 2 diabetes trials with CVD outcomes were registered in both 2009 and 2019 each (range 2-7). Conclusions: Despite increased emphasis on clinically-relevant outcomes, particularly with new therapeutics, &lt;2% of diabetes trials registered to ClinicalTrials.gov included CVD outcomes, which did not meaningfully increase from 2009. However, diabetes trials with CVD outcomes were primarily industry funded and well-designed. Given the importance of clinically-relevant outcomes, particularly the increased risk of CVD seen with diabetes, greater emphasis on CVD outcomes in diabetes-specific trials is needed.
Abstract 16322: Prognostic Value of Maximum Creatine Kinase-MB in Patients After Resuscitation From Out-of-Hospital Cardiac Arrest
Authors: Naoto Murakami, Nobuaki Kokubu, Jun Nakata, Takahiro Noto, Nobutaka Nagano, Junichi Nishida, Kazufumi Tsuchihashi, Tetsuji Miura
Journal: Circulation (2017)

Background: Decreased coronary perfusion during cardiac resuscitation damages myocardium even in cases without coronary stenosis. However, few studies have investigated the prognostic value of crea...
Impact of Center Experience with Donor Type and Treatment Platform on Outcomes: A Secondary Analysis BMT CTN 1101
Authors: Claudio G. Brunstein, Paul V O'Donnell, Brent R. Logan, Luciano J. Costa, Corey Cutler, Michael Craig, William J Hogan, Mary M. Horowitz, Mitchell E. Horwitz, Chatchada Karanes, John M. Magenau, Adriana Malone, John M McCarty, Joseph P. McGuirk, Lawrence E Morris, Andrew R. Rezvani, Witold Rybka, Rachel Salit, Sumithira Vasu, Mary Eapen, Ephraim J. Fuchs
Journal: Blood (2021)
Abstract 8938: The New Myokine Myonectin is Significantly Associated with Type 2 Diabetes in Elderly Patients
Authors: Andreas Leiherer, Axel Muendlein, Kathrin Geiger, Christoph H Saely, Barbara Larcher, Arthur Mader, Maximilian Maechler, Lukas Sprenger, Beatrix Mutschlechner, Magdalena Benda, Peter Fraunberger, Heinz Drexel
Journal: Circulation (2021)

Introduction: The novel myokine myonectin is predominantly expressed in skeletal muscle and is involved in the regulation of metabolic homeostasis. A putative association between myonectin and type 2 diabetes mellitus (T2DM) has been discussed controversially in current literature. Hypothesis: We hypothesize that there is an association between myonectin and T2DM at different ages - this is addressed in the present study. Methods: We measured myonectin in 410 vascular risk patients with a mean age of 66 years. Results: Myonectin did not correlate with age (r=-0.19; p=0.697). From our patients 219 (53%) were &gt;65 years, with a mean age of 74 years and 191 ≤65 years, with a mean age of 57 years. The prevalence of T2DM was 40.6% vs. 42.4% in the older as compared to the younger age group. Myonectin concentrations were significantly decreased in elderly patients with T2DM compared to non-diabetic subjects (1.8 vs. 4.2 ng/ml; p=0.002), whereas no significant difference was observed in younger patients (2.6 vs. 2.3 ng/ml; p=0.183). Concordantly, regression analysis revealed an unadjusted odds ratio (OR) of 0.24 [0.07-0.81] (p=0.021) for the association between myonectin and T2DM in elderly patients but not in younger patients (OR=1.08 [0.80-1.45]; p=0.609). The association between myonectin and T2D remained significant after adjusting for sex, body mass index, LDL cholesterol, HDL cholesterol, current smoking, as well as statin intake in elderly but remained non-significant in younger patients (OR=0.23 [0.07-0.81]; p=0.021 vs. OR=1.05 [0.76-1.46]; p=0.769). Conclusions: We conclude that plasma myonectin levels are significantly associated with T2DM, particularly in elderly vascular risk patients.
Favorable Modulation of Chimeric Antigen Receptor T Cells Safety and Efficacy By the Non-Covalent BTK Inhibitor Vecabrutinib
Authors: Mohamad M. Adada, Reona Sakemura, Michelle J. Cox, Caludia Manriquez-Roman, Elizabeth L. Siegler, Erin E. Tapper, Carli M. Stewart, Kendall J. Schick, Ismail Can, Ekene J. Ogbodo, Evandro D. Bezerra, Lionel A. Kankeu Fonkoua, Mehrdad Hefazi, Michael W. Ruff, Pietro Taverna, Judith A. Fox, Gloria Olivier, Susan L. Slager, Wei Ding, Sameer A. Parikh, Neil E. Kay, Saad S. Kenderian
Journal: Blood (2021)
Correlation Analysis of DNA Methylation Level and Clinical Characteristics in JMML Patients
Authors: Yuli Cai, Jingliao Zhang, Meihui Yi, Xiaoming Liu, Xiaoyan Zhang, Yang Wan, Lixian Chang, Li Zhang, Xiaojuan Chen, Ye Guo, Yao Zou, Yumei Chen, Yingchi Zhang, Wenyu Yang, Xiaofan Zhu
Journal: Blood (2021)
Splenomegaly Study (SMS): Which Etiologies for Unexplained Splenomegalies?
Authors: Guillaume Denis, Louis Terriou, Thomas Séné, Regis Costello, Martin Michaud, Claudia Hellé, Audrey Lagadec, Frédéric Bauduer, Laurence Sanhes, Christian Rose, Geoffrey Urbanski, Marc G. Berger
Journal: Blood (2021)
Definitive Hematopoietic Stem Cells Minimally Contribute to Embryonic Hematopoiesis
Authors: Bianca A Ulloa, Samima S Habbsa, Kathryn S Potts, Alana Lewis, Mia McKinstry, Sara Payne, Julio Flores, Anastasia Nizhnik, Maria Feliz Norberto, Christian Mosimann, Teresa V. Bowman
Journal: Blood (2021)
Parallel symposium A. 급성간부전(Acute Liver failure: ALF) : 급성 간부전의 치료
Authors: 최종영
Journal: Clinical and Molecular Hepatology (2010)

최근 의학 여러 분야에서 많은 발전이 있었지만, 급성 간부전은 사망률이 매우 높음에도 불구하고 뚜렷한 발전이 없었던 것이 사실이다. 급성 간부전의 원인으로 B형간염이 큰 부분을 차지하는 우리나라에서 2008-2009년 급성 A형간염으로 인한 급성 간부전 환자가 증가하여 과거에 비해 급성 간부전 환자가 일시적으로 증가함으로써 이에 대한 관심이 증가하게 되었다. 본고에서 근래 발표된 급성 간부전에 관한 문헌과 임상경험을 바탕으로 치료 분야를 요약하였다.1-6 급성 간부전은 다른 간질환에 비해서 발생빈도가 낮아, 치료에 대한 임상근거 수준이 매우 낮은 실정이며, 환자수도 적고, 사망률이 매우 높아 앞으로도 전향적, 무작위 임상연구는 이루어지기 어려울 것이다.
Extrachromosomal DNA: An Emerging Hallmark in Human Cancer
Authors: Sihan Wu, Vineet Bafna, Howard Y. Chang, Paul S. Mischel
Journal: Annual Review of Pathology Mechanisms of Disease (2021)

Human genes are arranged on 23 pairs of chromosomes, but in cancer, tumor-promoting genes and regulatory elements can free themselves from chromosomes and relocate to circular, extrachromosomal pieces of DNA (ecDNA). ecDNA, because of its nonchromosomal inheritance, drives high-copy-number oncogene amplification and enables tumors to evolve their genomes rapidly. Furthermore, the circular ecDNA architecture fundamentally alters gene regulation and transcription, and the higher-order organization of ecDNA contributes to tumor pathogenesis. Consequently, patients whose cancers harbor ecDNA have significantly shorter survival. Although ecDNA was first observed more than 50 years ago, its critical importance has only recently come to light. In this review, we discuss the current state of understanding of how ecDNAs form and function as well as how they contribute to drug resistance and accelerated cancer evolution.
Constructing germline research cohorts from the discarded reads of clinical tumor sequences
Authors: Alexander Gusev, Stefan Groha, Kodi Taraszka, Yevgeniy R. Semenov, Noah Zaitlen
Journal: Genome Medicine (2021)

Abstract Background Hundreds of thousands of cancer patients have had targeted (panel) tumor sequencing to identify clinically meaningful mutations. In addition to improving patient outcomes, this activity has led to significant discoveries in basic and translational domains. However, the targeted nature of clinical tumor sequencing has a limited scope, especially for germline genetics. In this work, we assess the utility of discarded, off-target reads from tumor-only panel sequencing for the recovery of genome-wide germline genotypes through imputation. Methods We developed a framework for inference of germline variants from tumor panel sequencing, including imputation, quality control, inference of genetic ancestry, germline polygenic risk scores, and HLA alleles. We benchmarked our framework on 833 individuals with tumor sequencing and matched germline SNP array data. We then applied our approach to a prospectively collected panel sequencing cohort of 25,889 tumors. Results We demonstrate high to moderate accuracy of each inferred feature relative to direct germline SNP array genotyping: individual common variants were imputed with a mean accuracy (correlation) of 0.86, genetic ancestry was inferred with a correlation of &gt; 0.98, polygenic risk scores were inferred with a correlation of &gt; 0.90, and individual HLA alleles were inferred with a correlation of &gt; 0.80. We demonstrate a minimal influence on the accuracy of somatic copy number alterations and other tumor features. We showcase the feasibility and utility of our framework by analyzing 25,889 tumors and identifying the relationships between genetic ancestry, polygenic risk, and tumor characteristics that could not be studied with conventional on-target tumor data. Conclusions We conclude that targeted tumor sequencing can be leveraged to build rich germline research cohorts from existing data and make our analysis pipeline publicly available to facilitate this effort.
The Safe Urban Harvests Study: A Community-Driven Cross-Sectional Assessment of Metals in Soil, Irrigation Water, and Produce from Urban Farms and Gardens in Baltimore, Maryland
Authors: Sara N. Lupolt, Raychel E. Santo, Brent F. Kim, Carrie Green, Eton Codling, Ana M. Rule, Rui Chen, Kirk G. Scheckel, Mariya Strauss, Abby Cocke, Neith G. Little, Valerie C. Rupp, Rachel Viqueira, Jotham Illuminati, Audrey Epp Schmidt, Keeve E. Nachman
Journal: Environmental Health Perspectives (2021)

Background: Emerging evidence suggests social, health, environmental, and economic benefits of urban agriculture (UA). However, limited work has characterized the risks from metal contaminant exposures faced by urban growers and consumers of urban-grown produce. Objectives: We aimed to answer community-driven questions about the safety of UA and the consumption of urban-grown produce by measuring concentrations of nine metals in the soil, irrigation water, and urban-grown produce across urban farms and gardens in Baltimore, Maryland. Methods: We measured concentrations of 6 nonessential [arsenic (As), barium (Ba), cadmium (Cd), chromium (Cr), lead (Pb), nickel (Ni)] and three essential [copper (Cu), manganese (Mn), zinc (Zn)] metals in soil, irrigation water, and 13 types of urban-grown produce collected from 104 UA sites. We compared measured concentrations to existing public health guidelines and analyzed relationships between urban soil and produce concentrations. In the absence of guidelines for metals in produce, we compared metals concentrations in urban-grown produce with those in produce purchased from farmers markets and grocery stores (both conventionally grown and U.S. Department of Agriculture–certified organic). Results: Mean concentrations of all measured metals in irrigation water were below public health guidelines. Mean concentrations of nonessential metals in growing area soils were below public health guidelines for Ba, Cd, Pb, and Ni and at or below background for As and Cr. Though we observed a few statistically significant differences in concentrations between urban and nonurban produce items for some combinations, no consistent or discernable patterns emerged. Discussion: Screening soils for heavy metals is a critical best practice for urban growers. Given limitations in existing public health guidelines for metals in soil, irrigation water, and produce, additional exposure assessment is necessary to quantify potential human health risks associated with exposure to nonessential metals when engaging in UA and consuming urban-grown produce. Conversely, the potential health benefits of consuming essential metals in urban-grown produce also merit further research. https://doi.org/10.1289/EHP9431
Loss of <i>iqgap1</i> (IQ Motif Containing GTPase Activating Protein 1) in Zebrafish Leads to Intracerebellar Hemorrhage, Morphological Abnormalities and Activates Hematopoietic Response
Authors: Sergey Prykhozhij, Lucia Caceres, Kevin Ban, Christopher McMaster, Johane M Robitaille, Jason N Berman
Journal: Blood (2021)
Nanatinostat (Nstat) and Valganciclovir (VGCV) in Relapsed/Refractory (R/R) Epstein-Barr Virus-Positive (EBV +) Lymphomas: Final Results from the Phase 1b/2 VT3996-201 Study
Authors: Bradley M. Haverkos, Onder Alpdogan, Robert Baiocchi, Jonathan E Brammer, Tatyana A. Feldman, Marcelo Capra, Elizabeth A Brem, Santosh M Nair, Phillip Scheinberg, Juliana Pereira, Leyla Shune, Erel Joffe, Afton Katkov, Robert McRae, Ivor Royston, Lisa Rojkjaer, Pierluigi Porcu
Journal: Blood (2021)
Tislelizumab Plus GemOx in Patients with Relapsed/Refractory Classic Hodgkin Lymphoma: A Single-Arm, Multi-Center Phase II Trial
Authors: Kaiyang Ding, Hailing Liu, Haiyan Yang, Lei Cao, Xiaoli Zhao, Wei Wu, Xiaoyan Zhang, Li Wang, Wei Xu, Huayuan Zhu, Jianyong Li, Lei Fan
Journal: Blood (2021)
Ribonuclease 7 polymorphism rs1263872 reduces antimicrobial activity and associates with pediatric urinary tract infections
Authors: Keith R. Pierce, Tad Eichler, Claudia Mosquera Vasquez, Andrew L. Schwaderer, Aaron Simoni, Steven Creacy, David S. Hains, John D. Spencer
Journal: Journal of Clinical Investigation (2021)

Ribonuclease 7 (RNase 7) is an antimicrobial peptide that prevents urinary tract infections (UTI); however, it is yet unknown how RNASE7 genetic variations affect its antimicrobial activity and its mitigation of UTI risk. This study determined whether the RNASE7 SNP rs1263872 is more prevalent in children with UTI and defined how rs1263872 affects RNase 7's antimicrobial activity against uropathogenic E. coli (UPEC). We performed genotyping for rs1263872 in 2 national UTI cohorts, including children enrolled in the Randomized Intervention for Children with Vesicoureteral Reflux trial or the Careful Urinary Tract Infection Evaluation study. Genotypes from these cohorts were compared with those of female controls with no UTI. To assess whether rs1263872 affects RNase 7's antimicrobial activity, we generated RNase 7 peptides and genetically modified urothelial cultures encoding wild-type RNase 7 and its variant. Compared with controls, girls in both UTI cohorts had an increased prevalence of the RNASE7 variant. Compared with the missense variant, wild-type RNase 7 peptide showed greater bactericidal activity against UPEC. Wild-type RNase 7 overexpression in human urothelial cultures reduced UPEC invasive infection compared with mutant overexpression. These results show that children with UTI have an increased prevalence of RNASE7 rs1263872, which may increase UTI susceptibility by suppressing RNase 7's antibacterial activity.
A Pharmacist-Managed Hydroxyurea Prescribing Protocol Improves Uptake and Optimization Among Patients with Sickle Cell Disease within the Southern Alberta Rare Blood and Bleeding Disorders (SARBBD) Comprehensive Care Program
Authors: Cameron Roessner, Trudy Sale, Man-Chiu Poon, Dawn Goodyear, Adrienne Lee, Natalia Rydz
Journal: Blood (2021)
Recent progress and new challenges in modeling of human pluripotent stem cell-derived blood-brain barrier
Authors: Li Yan, Rebecca A Moriarty, Kimberly M Stroka
Journal: Theranostics (2021)

The blood-brain barrier (BBB) is a semipermeable unit that serves to vascularize the central nervous system (CNS) while tightly regulating the movement of molecules, ions, and cells between the blood and the brain. The BBB precisely controls brain homeostasis and protects the neural tissue from toxins and pathogens. The BBB is coordinated by a tight monolayer of brain microvascular endothelial cells, which is subsequently supported by mural cells, astrocytes, and surrounding neuronal cells that regulate the barrier function with a series of specialized properties. Dysfunction of barrier properties is an important pathological feature in the progression of various neurological diseases. In vitro BBB models recapitulating the physiological and diseased states are important tools to understand the pathological mechanism and to serve as a platform to screen potential drugs. Recent advances in this field have stemmed from the use of pluripotent stem cells (PSCs). Various cell types of the BBB such as brain microvascular endothelial cells (BMECs), pericytes, and astrocytes have been derived from PSCs and synergistically incorporated to model the complex BBB structure in vitro. In this review, we summarize the most recent protocols and techniques for the differentiation of major cell types of the BBB. We also discuss the progress of BBB modeling by using PSC-derived cells and perspectives on how to reproduce more natural BBBs in vitro.
Safety and Tolerability of Fedratinib (FEDR), an Oral Inhibitor of Janus Kinase 2 (JAK2), in Patients with Intermediate- or High-Risk Myelofibrosis (MF) Previously Treated with Ruxolitinib (RUX): Results from the Phase 3b FREEDOM Trial
Authors: Vikas Gupta, Abdulraheem Yacoub, Srdan Verstovsek, Ruben A. Mesa, Claire N. Harrison, Giovanni Barosi, Jean-Jacques Kiladjian, H. Joachim Deeg, Salman Fazal, Lynda Foltz, Ryan J. Mattison, Carole B. Miller, Vinod Parameswaran, Vishwanath Gharpure, Christopher Hernandez, Tianhua Wang, Moshe Talpaz
Journal: Blood (2021)